Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTION: Tildrakizumab + Abiraterone in mCRPC
NCT04458311Phase 2Terminated
- Sponsor
- The Institute of Cancer Research
- Start
- Dec 2020
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of tildrakizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by The Institute of Cancer Research. Started Dec 2020; status: terminated.
02
Drugs
tildrakizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04458311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458311.